Thomas Alan Fraser

US Patent:

20020031497, Mar 14, 2002

Filed:

Apr 26, 2001

Appl. No.:

09/843270

Inventors:

Thomas Fraser - Newton MA, US
Jonathan Dinsmore - Brookline MA, US

Assignee:

Diacrin, Inc.

International Classification:

A61K045/00
C12N005/06

US Classification:

424/093700, 435/325000

Abstract:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

US Patent:

61958042, Mar 6, 2001

Filed:

Aug 10, 1999

Appl. No.:

9/371764

Inventors:

Thomas M Fraser - Hampstead NH

International Classification:

A41D 1900

US Classification:

21612

Abstract:

A pair of golf gloves each having loop and pile interfaces at specific locations that fasten together as a golfer grasps a golf club, and they aid the golfer to properly grasp, hold and maintain a preferred neutral hold on a golf club during back swing and forward swing to achieve a good golf shot.

US Patent:

44436084, Apr 17, 1984

Filed:

May 24, 1982

Appl. No.:

6/381528

Inventors:

Walter C. Herlihy - Cambridge MA
Thomas H. Fraser - Newtonville MA

Assignee:

Repligen Corporation - Cambridge MA

International Classification:

C07H 1526

US Classification:

546268

Abstract:

An in vitro enzymatic process which efficiently converts (+,-)-tropicamide to essentially pure (+), (-)-tropicamide O-. beta. -D-glucuronide. This product is then separated, advantageously, into the novel compounds (+)-tropicamide O-. beta. -D-glucuronide and (-)-tropicamide O-. beta. -D-glucuronide. The products disclosed herein absorb ultraviolet light, and, thus, can be incorporated into suitable plastic films which are then useful for screening out harmful ultraviolet radiation for the protection of packaged goods. Also the products can be used to protect the skin against burning by sunlight.

US Patent:

46297928, Dec 16, 1986

Filed:

Sep 9, 1985

Appl. No.:

6/773714

Inventors:

Walter C. Herlihy - Cambridge MA
Thomas H. Fraser - Newtonville MA

Assignee:

Repligen Corporation - Cambridge MA

International Classification:

C07H 1526
B01D 1508

US Classification:

546268

Abstract:

An in vitro enzymatic process which efficiently converts (+,-)-tropicamide to essentially pure (+), (-)-tropicamide O-. beta. -D-glucuronide. This product is then separated, advantageously, into the novel compounds (+)-tropicamide O-. beta. -D-glucuronide and (-)-tropicamide O-. beta. -D-glucuronide. The products disclosed herein absorb ultraviolet light, and, thus, can be incorporated into suitable plastic films which are then useful for screening out harmful ultraviolet radiation for the protection of packaged goods. Also, the products can be used to protect the skin against burning by sunlight.

US Patent:

45886865, May 13, 1986

Filed:

Jan 31, 1984

Appl. No.:

6/575521

Inventors:

Walter C. Herlihy - Cambridge MA
Thomas H. Fraser - Newtonville MA

Assignee:

Repligen Corporation - Cambridge MA

International Classification:

C12P 1958
C07P 4100

US Classification:

435 77

Abstract:

An in vitro enzymatic process which efficiently converts (+,-)-tropicamide to essentially pure (+), (-)-tropicamide O-. beta. -D-glucuronide. This product is then separated, advantageously, into the novel compounds (+)-tropicamide O-. beta. -D-glucuronide and (-)-tropicamide O-. beta. -D-glucuronide. The products disclosed herein absorb ultraviolet light, and, thus, can be incorporated into suitable plastic films which are then useful for screening out harmful ultraviolet radiation for the protection of packaged goods. Also, the products can be used to protect the skin against burning by sunlight.

US Patent:

62773720, Aug 21, 2001

Filed:

Apr 19, 1995

Appl. No.:

8/424855

Inventors:

Thomas Fraser - Newton MA
Jonathan Dinsmore - Brookline MA

Assignee:

Diacrin, Inc. - Charlestown MA

International Classification:

A01N 6300
C12N 502
C12N 506

US Classification:

424 937

Abstract:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e. g. , an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e. g. , by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e. g.